🔗 Share this article

As the US continues making unprecedented adjustments to its vaccine schedules, an unexpected name has surfaced unexpectedly: Høeg, a US-based sports physician and public health researcher who initially gained attention by casting doubt on COVID-19 shots in the pandemic and has concentrated on alleged deaths after Covid immunization in her brief position at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Childhood Immunization Schedule

Agency leaders planned to reveal radical revisions to the pediatric immunization program earlier this month, bringing the US with Denmark’s immunization schedule, sources say – a substantial departure that would place the US out of alignment with a large portion of the international standard with little proof for improved outcomes. The planned update has been postponed until the coming year.

Instead of Vinay Prasad, Høeg is set to present at the meeting. She was recently named acting director of the FDA’s drug evaluation center, the fifth person to lead the center this calendar year.

Consolidating Power at the Regulatory Body

The acting appointment may indicate a closer partnership between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it suggests a greater focus upon dismantling long-standing vaccines at the FDA.

The new acting director has repeatedly called for discontinuing some pediatric shot schedules in the US in order to be more similar to the Danish model, a country with comprehensive healthcare and a number of inhabitants approximately the size of Wisconsin’s.

In her initial statements, she has continued to focus on vaccines – traditionally the responsibility of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Doubts Over Background

Dr. Høeg has no obvious background in drug development, regulation or management, which has been typical for past directors of the CBER. She has served at the FDA as a top consultant to the FDA chief and CBER since earlier this year.

“It seems she lacks to have the requisite experience” for running the drug-regulation department, remarked Jonathan Howard. “She has not conducted a randomized controlled trial. She has no expertise in leading a major agency. She has no expertise in industry regulation.”

Past commissioners of CBER would “grasp regulatory frameworks and the underlying principles of pharmaceutical innovation”, noted Janet Woodcock. “Objectively, she has not acquired the sort of resume that prior appointees who ran the center have had.”

The drug center has an enormous portfolio at the FDA, the former commissioner stated.

“Many people just pays attention on the new drug program, but the generic drug division approves numerous generic drugs. There is also a biosimilars program, non-prescription drug unit and more, and every single one have to be supervised,” Dr. Woodcock explained. “The area you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Additionally, a significant administrative element to the role, which supervises in excess of 5,000 employees. “It is a huge administrative position, if you execute it properly,” Woodcock said.

Official Statement and Controversial Initiatives

In response to questions about Høeg’s credentials and whether this appointment signifies greater collaboration among FDA leaders on vaccines, a spokesperson said that the “concerns rely on incorrect premises”.

“Her experience matches the functions of her role,” the official stated, pointing to the time Dr. Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's controversial priority voucher program, a controversial rapid drug-approval program that reportedly troubled her former heads. “How are these drugs being picked for this voucher program? Who takes the choices?” Howard questioned. “There is a lot of confidentiality occurring at the regulatory body right now.”

Overall, he remarked, “the FDA looks to be trending towards less stringent regulations of pharmaceuticals, with the exception of immunizations.”

Established Past Work on Vaccines

With vaccines, Høeg has a clearer, if problematic, history, critics observe. She authored a research paper using non-validated crowd-sourced reports to estimate the frequency of myocarditis following COVID-19 immunization. She consulted for the Florida chief medical officer Joseph Ladapo, who allegedly have modified findings to imply COVID-19 vaccinations are riskier than they are.

Part of her “desired changes” for the new government encompassed revising regulations for recently developed shots and ending “non-essential” vaccines, she said following the vote on a podcast. At the agency, Høeg has allegedly suggested barring teenage boys from receiving COVID-19 vaccinations.

“She’s an complete dogmatist who commences with her beliefs and works backwards to retrofit the data in a very disingenuous, untruthful fashion,” Howard stated.

Taking Control and a “Revenge Tour”

Dr. Høeg aligned with other dissenters, {like|